Please login to the form below

Not currently logged in
Email:
Password:

accelerated review

This page shows the latest accelerated review news and features for those working in and with pharma, biotech and healthcare.

EMA starts rapid review of Shire’s HAE antibody

EMA starts rapid review of Shire’s HAE antibody

Shire could be months away from its first regulatory approval for hereditary angioedema (HAE) candidate lanadelumab as the EMA starts an accelerated review of the drug. ... The EMA accelerated review means a verdict is due in 150 days rather than the

Latest news

  • Ex-GSK head Witty to head group overseeing UK fast-track scheme Ex-GSK head Witty to head group overseeing UK fast-track scheme

    be selected for the Government’s new Accelerated Access Pathway (AAP), due to come into effect next April. ... Last October, the independent Accelerated Access Review (AAR) led by Sir High Taylor set out a series of recommendations for streamlining the

  • NICE: We're the institute of 'yes' NICE: We're the institute of 'yes'

    The Strategy also made a series of recommendations that would overlap with and supplement the Accelerated Access Review, including parallel processing of MHRA and NICE assessments, a single appraisal process and ... The event also heard industry praise

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    Gilead has also filed for the sofosbuvir, velpatasvir and voxilaprevir therapy in the EU, winning an accelerated review from the EMA in January.

  • Mixed news for pharma on UK's Accelerated Access Review Mixed news for pharma on UK's Accelerated Access Review

    Mixed news for pharma on UK's Accelerated Access Review. New funding will go towards ASHNs, SME’s and the Pathway Transformation Fund to name a few. ... The scheme is the first stage in the independent Accelerated Access Review (AAR) - designed to

  • Keytruda is first FDA-approved drug for molecular indication Keytruda is first FDA-approved drug for molecular indication

    Merck has been granted accelerated approval for Keytruda in this indication based on the results of five uncontrolled single-arm clinical trials involving 149 patients, so it will have to provide ... The new approval comes just hours after Merck claimed

More from news
Approximately 1 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Uncertainty, austerity and Brexit Uncertainty, austerity and Brexit

    Alongside this, rumours that NHS England was planning to include biosimilars on the Accelerated Access Pathway, the flagship policy intervention designed to speed up the use of innovative products, would amount ... Sciences Industrial Strategy and the

  • Lighting the way Lighting the way

    Lighting the way. How the UK’ s Accelerated Access Review aims to guide medical innovations to their destination. ... She noted that engaging with the government on the new Life Sciences Strategy (see p7) and the Accelerated Access Review were among

  • Market access in Europe: balancing access and affordability Market access in Europe: balancing access and affordability

    In October 2016, the Accelerated Access Review (AAR) published its recommendations to the UK government. ... Furthermore, not all of these technologies would necessarily complete the Accelerated Access Pathway.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics